Amplification of the antitumoral response by blocking co-inhibitory receptors like PD1, PD-L1 or PD-L2 and CTLA-4 has resulted in a sustained, positive clinical outcome in several cancer types [355]. The gene discussed is PDCD1LG2; the disease is cancer.